Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could spot liver cancer sooner

NCT ID NCT07319299

Diagnosis Sponsor: Mahidol University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a new blood test score, called GAAD, can detect liver cancer earlier in people with chronic liver disease. The GAAD score combines a person's gender, age, and two blood markers (AFP and PIVKA-II). Researchers will compare the GAAD score to standard ultrasound and AFP tests in 2,100 participants over 24 months. The goal is to see if the GAAD score improves detection and reduces false alarms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GAAD score (blood test combining gender, age, AFP, and PIVKA-II)
What this could lead to
If successful, the GAAD score could become a standard, more accurate blood test to catch liver cancer early in people with chronic liver disease.
What could go wrong
This is a diagnostic study, not a treatment. The GAAD score may not prove significantly better than current methods, and results may not apply outside the specific patient group studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults with chronic liver disease who have an indication for hepatocellular carcinoma (HCC) surveillance, including one or more of the following: * Liver cirrhosis of any etiology (e.g., chronic hepatitis B virus \[HBV\], chronic hepatitis C virus \[HCV\], metabolic dysfunction-associated steatohepatitis \[MASH\], or alcohol-related liver disease \[ALD\]) * Non-cirrhotic chronic liver disease (e.g., HCV, MASH, or ALD) with evidence of stage F3 fibrosis * Chronic HBV infection with a clinical diagnosis of non-cirrhotic liver disease Exclusion Criteria: * Diagnosis of any active malignancy other than non-melanoma skin cancer * History of previously diagnosed malignancy, including prior hepatocellular carcinoma * Life expectancy of less than 2 years * Use of vitamin K antagonists within 1 week prior to enrollment * Pregnant or breastfeeding women * Estimated glomerular filtration rate (GFR) \< 60 mL/min/1.73 m² * Significant hepatic decompensation or Child-Pugh class C liver disease * Unwillingness or inability to undergo computed tomography (CT) or magnetic resonance imaging (MRI) * Unwillingness or inability to provide informed consent or to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol related liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcoholic liver disease chronic hepatitis B virus infection chronic hepatitis C virus infection cirrhosis of liver Fibrosis hepatitis B virus infection hepatocellular carcinoma liver disorder metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis HBV infection Hepatecellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Medicine Siriraj Hospital

    Bangkoknoi, Bangkok, 10700, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.